11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to (225)Ac-PSMA-617 therapy.

          Related collections

          Author and article information

          Journal
          J. Nucl. Med.
          Journal of nuclear medicine : official publication, Society of Nuclear Medicine
          Society of Nuclear Medicine
          1535-5667
          0161-5505
          Dec 2016
          : 57
          : 12
          Affiliations
          [1 ] Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany clemens.kratochwil@med.uni-heidelberg.de.
          [2 ] European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany.
          [3 ] Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
          [4 ] Department of Nuclear Medicine, RWTH University Hospital Aachen, Aachen, Germany; and.
          [5 ] Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany.
          Article
          jnumed.116.178673
          10.2967/jnumed.116.178673
          27390158
          c0a9a1d9-a208-49af-afdd-98508011536b
          History

          225Ac,PSMA,alpha-therapy
          225Ac, PSMA, alpha-therapy

          Comments

          Comment on this article